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ABSTRACT: Clostridial neurotoxins reversibly block neuro-
nal communication for weeks and months. While these
proteolytic neurotoxins hold great promise for clinical
applications and the investigation of brain function, their
paralytic activity at neuromuscular junctions is a stumbling
block. To redirect the clostridial activity to neuronal
populations other than motor neurons, we used a new self-
assembling method to combine the botulinum type A protease
with the tetanus binding domain, which natively targets central
neurons. The two parts were produced separately and then
assembled in a site-speciﬁc way using a newly introduced
‘protein stapling’ technology. Atomic force microscopy
imaging revealed dumbbell shaped particles which measure
∼23 nm. The stapled chimera inhibited mechanical hypersensitivity in a rat model of inﬂammatory pain without causing either
ﬂaccid or spastic paralysis. Moreover, the synthetic clostridial molecule was able to block neuronal activity in a deﬁned area of
visual cortex. Overall, we provide the ﬁrst evidence that the protein stapling technology allows assembly of distinct proteins
yielding new biomedical properties.
■ INTRODUCTION
Long-term and reversible silencing of selected central nervous
system (CNS) areas and neuronal subpopulations in freely
moving organisms would beneﬁt both neuroscience and clinical
medicine. One way to meet these diﬃcult requirements is to re-
engineer and utilize clostridial neurotoxins.1−3 These toxins
target neuronal synapses and neuromuscular junctions, enter
presynaptic terminals, and then proteolyze unique SNARE
proteins, thereby stopping neurotransmitter release.4−6 Neuro-
nal activity resumes when the proteolyzed proteins are replaced
by de novo synthesized SNARE molecules in the active zones of
presynaptic terminals.7,8
In nature, clostridial neurotoxinsproduced by anaerobic
Clostridium bacteriaselectively target motor functions to
paralyze the intoxicated organism and gain a rich anaerobic
environment upon the victim’s death. Seven botulinum toxins
(designated A-G) from the genus Clostridium botulinum
inactivate cholinergic motor neurons to cause ﬂaccid paralysis.7
The blood-brain barrier is impenetrable to botulinum neuro-
toxins and therefore all eﬀects of botulinum poisoning are
peripheral. In contrast to botulinum neurotoxins, tetanus toxin
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produced by Clostridium tetanitraverses motor neurons, via
retrograde vesicular traﬃc,9 to inactivate inhibitory interneurons
in the spinal cord, causing rigid muscle paralysis.10 This route to
the spinal cord is utilized by C. tetani upon wound infection; but
experimentally almost all central neurons (glutamatergic,
glycinergic, etc.) can be targeted by tetanus toxin, leading to a
blockade of neurotransmitter release.11
The major stumbling block in utilizing clostridial toxins for
probing CNS functions is their life-threatening paralytic
activity.10 For example, when toxin is injected in a deﬁned
CNS area, its entry into the bloodstream can still lead to
widespread paralysis. Clearly, non-motor-targeted versions of
clostridial toxins would exclude paralytic actions and thus allow
safe interrogation of CNS functions and new therapeutic
applications. Our recent investigation of the reassembled
botulinum neurotoxin type A, which carries an extended linker,
demonstrated that it is as eﬀective as native type A toxin in
inactivating central neurons but has a reduced potency at
neuromuscular junctions.12,13 This was a fortuitous discovery,
which could be accounted for by the reduced ability of the
elongated toxin to enter tight neuromuscular junctions covered
by Schwann cells. At high doses, the reassembled botulinum
neurotoxin type A still causes ﬂaccid paralysis (see Results
section), and therefore we attempted to produce a truly
nonparalytic neuronal blocker which combines the highly
eﬃcient botulinum protease and the CNS-targeting tetanus
domain. Here we describe creation and properties of this new
clostridial chimera which eﬃciently targets central neurons,
blocks central nervous functions, and yet does not cause any
paralysis.
■ EXPERIMENTAL PROCEDURES
Plasmids and Sequences. mCherry fused to Tetanus toxin
Binding Domain (TBD) was made by introducing the mCherry
sequence from pmCherry-C1 vector (Clontech) into the EcoRI
restriction site of pGEX-KG, followed by the Clostridium tetani
TBD sequence (codon optimized for E. coli expression and
synthesized by Eurogentec, from amino acids 856−1315 of the
NCBI reference sequence NP_783831.1) into the SacI
restriction site. The plasmid for the expression of TBD fused
to synaptobrevin was prepared by introducing the Rattus
norvegicus synaptobrevin 2 sequence (codon optimized for E.
coli expression and synthesized by Eurogentec, from amino acids
3−84 of the NCBI reference sequence NP_036795.1) into the
XhoI restriction site of pGEX-KG in front of the TBD sequence
in the above pGEX vector. Botulinum neurotoxin A-derived
LcTd-SNAP-25 has been described previously.12 The Rattus
norvegicus syntaxin 1 stapling peptide (amino acids 201−245 of
the NCBI reference sequence NP_446240.2) is C-terminally
amidated and linked at the N-terminus to either ﬂuorescein or
TAMRA through an aminohexanoic acid spacer (synthesized by
Peptide Synthetic, UK).
Protein Preparation and Assembly Reaction. mCherry
TBD, botulinum LcTd-SNAP25, and synaptobrevin TBD were
expressed in the BL21 strain of E. coli. Brieﬂy, all proteins were
expressed as GST C-terminal fusions cleavable by thrombin.
Proteins fused to GST were puriﬁed on glutathione-Sepharose
beads (GE Healthcare) and eluted from the beads in 20 mM
Hepes, pH 7.3, 100 mM NaCl (Buﬀer A), using thrombin.
Further puriﬁcation was achieved by gel ﬁltration using a
Superdex 200 10/200 GL column (GE Healthcare). Protein
concentration was determined using the BCA protein assay kit
(Pierce). The clostridial chimera was assembled by mixing the
two clostridial fragments with the syntaxin peptide for 30 min at
20 °C, with each component at a 5 μM concentration, in the
presence of 0.4% octyl glucoside. To visualize SNARE
assemblies, SDS-PAGE was performed at 4 °C, and the gels
were stained with Coomassie blue.
Neuronal Cultures and Confocal Imaging. Hippocampal
neurons were cultured as previously described.14 Brieﬂy, the
hippocampi were dissected from E18 BL21 mice and dissociated
with 0.25% trypsin and trituration. The cells were counted and
plated on 18-mm glass coverslips treated with 1 mg/mL poly
lysine in borate buﬀer. The plating media was MEM (Gibco
#11095) containing 0.6% glucose and 10% horse serum. After 3−
4 h the coverslips were transferred to glia-conditioned media
comprising Neurobasal (Gibco #21103) supplemented with
glutamax and B27 serum-free supplement. The hippocampal
neurons were used after 14 div and treated as previously
described.15 Neurons in Figure 3A were treated with ﬂuorescein-
linked chimera (10 nM) for 5 min in the presence of high K+,
then ﬁxed and processed for immunocytochemistry using an
anti-synaptobrevin antibody. Coverslips were imaged using a
Zeiss LSM 710 confocal microscope. Dorsal root ganglia
(DRGs) neurons were prepared from neonatal Sprague−Dawley
rats (2−8 days old) killed by cervical dislocation and then
decapitated. Approximately 40−45 DRGs were removed from
the vertebral column and transferred into Hank’s Balanced Salt
Solution (HBSS, Invitrogen). Nerve trunks and connective tissue
were dissected away and the DRGs were placed in Neuro-
basalTM medium (Gibco, Life Technologies) containing 0.25%
collagenase (type IV, Worthington) for 60 min at 37 °C. After
washing with fresh Neurobasal medium (containing B27
supplement, Gibco, Life Technologies), ganglia were dissociated
by trituration using a ﬁre-polished Pasteur pipet. Cells were
washed in fresh Neurobasal medium and triturated again using a
smaller bore ﬁre-polished pipet to produce a suspension of single
cells. Cells were concentrated by centrifugation at 1000 r.p.m.
(110 g) for 5 min and the resulting pellet was resuspended in
neuronal culture medium containing B27 supplement, 1%
penicillin−streptomycin solution, 1% L-glutamine, 100 ng/mL
NGF (Alomone laboratories), and 2% cytosine β-D-arabinofur-
anoside (AraC, Sigma). The neuronal suspension was then
slowly placed on poly(L-lysine) and laminin precoated glass
bottomed culture dishes (MatTek Corproration) and incubated
for 24 h at 37 °C in a humidiﬁed incubator gassed with 5%CO2 in
air. After 24−48 h of incubation, 10 nM TAMRA-linked chimera
and 5 μg/mL Alexa Fluor 488-conjugated Griﬀonia simplicifolia
IB4 (Invitrogen) were added to a 35 mm glass bottomed culture
dishes. After a 15 min exposure in the dark, the culture was
washed 3 times with clean Neurobasal culture medium before
live imaging commenced. All live-cell images were taken with a
confocal laser-scanning microscope (Zeiss LSM 710).
AFM Imaging. Puriﬁed clostridial chimera (500 nM) was
diluted 50-fold in 100 mMNaCl, 50 mMHepes-Na, pH 7.5; and
50 μL of the sample was allowed to adsorb to freshly cleavedmica
disks for 10 min. The sample was washed with high purity water
(Sigma-Aldrich) and dried under nitrogen. Imaging was
performed with aMultimode atomic forcemicroscope controlled
by a Nanoscope IIIa controller (Bruker, Santa Barbara, CA,
USA). Dry samples were imaged using the tapping mode. The
silicon probes used (OMCL-AC160TS, Olympus, Tokyo, Japan)
had a typical tip radius of 6.8 nm, a resonance frequency of ∼300
kHz, and a spring constant of 40 N/m. The applied imaging force
was kept as low as possible (between 85% and 90% of the free
amplitude).
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Immunoblotting. Hippocampal or DRG neurons were
incubated for 20 h with the indicated concentration of either
chimera or the control protein, lysed in 2% SDS, benzonase (250
U/mL, Novagen), 2 mM MgCl2, 60 mM Tris-HCl, pH 6.8.
Botulinum-induced cleavage of SNAP-25 was evaluated by
immunoblotting using an anti-SNAP-25 antibody (clone SMI 81,
Covance) which recognizes both intact and cleaved SNAP-25.
The percentage of the cleaved SNAP-25 was estimated by
densitometry analysis using Quantity One software (Bio-Rad).
Circadian Rhythms. Organotypic slices of suprachiasmatic
nucleus were obtained from neonatal mice (10 days of age)
carrying a knock-in mutation of the Period2 circadian clock gene
that encodes Per2-luciferase fusion protein.16 Following a 3-day
initial period to conﬁrm robust circadian oscillation, the slices
were bath treated with 5 nM of the clostridial chimera and
recording continued for further 9 days. Per2-driven bio-
luminescence was recorded using photomultiplier tubes
(Hamamatsu), as described elsewhere.17
HemidiaphragmAssay. Left phrenic nerve-hemidiaphragm
preparations frommale inbredmice (Balb/c) were incubated in a
37 °C bath containing the Krebs-gelatin buﬀer gassed with 95%
O2/5% CO2. Muscle contractions triggered by stimulation of the
nerve with a supra-maximal voltage (∼3 V, 1 Hz, 0.2 ms) were
measured using an isometric force transducer (FMI, Seeheim,
Germany) linked to a bridge ampliﬁer ML110 and a Powerlab/
4SP 4 channel recorder (ADInstruments, Chalgrove, UK). The
hemidiaphragm resting tension was increased stepwise during
the equilibration period until a reproducible twitch was observed.
Once the muscle twitch responses to nerve stimulation had
stabilized and were of constant size for at least 30 min, the Krebs
solution was replaced with one containing native type A toxin or
reassembled toxin and stimulation resumed. The decrease in
contraction was calculated in relation to the contractions just
before toxin addition.18 Native botulinum neurotoxin (580 pM)
used for reference (HPA, Potters Bar, UK) had eﬃcacy of 20 000
LD50/mL.
Biological Testing. Adult C57 BL6 mice (20−25 days of
age; average weight 20 g) were injected intravenously or
intramuscularly with the clostridial chimera or reassembled
botulinum neurotoxin (500 ng). The proteins were diluted in
Hartmann’s Solution to achieve a required dose for the injection
volume of 50 μL. Animals were replaced in their cages and
monitored every 6 h for 4 days. The end point of the experiment
was the appearance of weakness of the musculature of the limbs
either ipsilateral to the injection point or bilaterally. Surviving
animals were sacriﬁced after 7 days.
Visual Cortex Experiments. A portion of the skull overlying
the occipital cortex was drilled on one side of the skull. The
injections into the visual cortex were done using a glass
micropipet, connected to an injector, at the following
coordinates (in mm with respect to lambda): AP, 0; ML, 4.5;
1.2 below dura.19 Clostridial chimera (50 nM, 1 μL, equivalent to
7.5 ng) or vehicle (rat serum albumin 2%, in PBS, 1 μL) was
injected into the visual cortex of P40 Long Evans rats.
Electrophysiological, anatomical, and biochemical analyses
were performed 4−8 days after toxin delivery. For electro-
physiological recordings, rats were anesthetized with Hypnorm/
Hypnovel (3.75 mL/kg body weight) and placed in a stereotaxic
apparatus. Recordings were performed as described previ-
ously.19,20 Both eyes were ﬁxed by means of adjustable metal
rings surrounding the external portion of the eye bulb, and optic
disk locations were projected onto a tangent screen to determine
the vertical meridian. Body temperature during the experiments
was constantly monitored with a rectal probe and maintained at
37 °C with a heating blanket. The electrocardiogram was also
continuously monitored. A portion of the skull overlying the
occipital cortex was drilled on one side of the skull, and a
tungsten electrode (FHC; 1 MΩ) was mounted on a three-axis
motorized micromanipulator and inserted into the portion of the
visual cortex previously injected with clostridial chimera (4.5 mm
lateral from midline and in correspondence with lambda). Visual
evoked potentials (VEPs) were recorded at depths of 100 and
400 μm within the cortex. Steady-state VEPs were recorded in
response to reversal (4 Hz) of a horizontal sinusoidal grating
(spatial frequency, 0.07 cycles/deg; contrast 10%, 20%, 30%,
90%), generated by computer on a display (Sony; 40 × 30 cm;
mean luminance 15 cd/m2) by a VSG card (Cambridge Research
Systems). Signals were ampliﬁed (1000-fold), band-pass ﬁltered
(0.5−100 Hz), and fed into a computer for storage and analysis.
At least 80 events were averaged in synchrony with the stimulus
contrast reversal. VEP amplitude was quantiﬁed by measuring
the amplitude of the second harmonic of the Fourier transform
computed from the recorded signal, as previously described,21
using a custom-made application based on the LabView software.
The response to a blank stimulus (0% contrast) was also
frequently recorded to estimate noise. In each animal, contrast
threshold curves were measured close to (<500 μm) or far from
(>500 μm) the injection site. In each animal, at least six
penetrations were performed (3 ‘close to’ and 3 ‘far from’ the
injection). Visual responsiveness was determined as the signal-
to-noise ratio, that is, the ratio between VEP amplitude at a given
contrast and blank amplitude. In each animal, we compared
visual responses close to and far from the injection by plotting a
contrast threshold curve, in which responsiveness at a given
contrast was normalized to the values measured at 90% contrast
in penetrations distant from the delivery site. Analysis of VEP
responses was performed blind to experimental treatment. For
immunohistochemistry, the animals were deeply anesthetized
with chloral hydrate and perfused through the heart with freshly
prepared 4% paraformaldehyde in 0.1 M phosphate buﬀer, pH
7.4. Tissues were dissected and postﬁxed for 2 h at 4 °C. Brain
sections (40 μm thick) were cut with a microtome. Sections were
blocked with 10% normal horse serum in PBS containing 0.25%
Triton X-100 and then incubated overnight at room temperature
with a rabbit polyclonal antibody to cleaved SNAP-25 (1:200
dilution; kind gift of O. Rossetto, University of Padua, Italy). On
the following day, sections were incubated with Rhodamine Red
X-conjugated secondary antibody (1:500, Jackson ImmunoR-
esearch) for 2 h at room temperature. Sections were washed in
PBS and incubated for 5 min with YoYo-1 (1:500 in PBS;
Invitrogen), then washed again in PBS and mounted using an
antifading agent (Vectashield; Vector Laboratories). Images
were acquired using a Leica confocal laser-scanning microscope
and a 10× objective. Immunoblotting was performed as
described previously.22,23 Cortical parts were excised and lysed
using a buﬀer containing 1% Triton X-100, 10% glycerol, 150
mMNaCl, 10 mM EDTA, 0.1 mMNa3VO4, 1 μg/mL leupeptin,
1 μg/mL aprotinin, 1 mMPMSF, and 20 mMTris-HCl, pH 7.5).
Proteins (10 μg) were separated by electrophoresis and
transferred to blotting paper, which was then incubated with
primary antibody overnight at 4 °C (anticleaved SNAP-25, 1:500
dilution; antitubulin antibody 1:15 000 dilution, Sigma). Blots
were then reacted with HRP-conjugated secondary antibodies
(Jackson ImmunoResearch) and developed using an enhanced
chemiluminescence kit (GE Healthcare).
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Inﬂammatory Pain Experiments. Experiments were
carried out on male Sprague−Dawley rats (∼200 g body weight
at the beginning of the experiment) from the colony at University
College London. Animals were housed in their home cage
controlled for temperature (21 °C) and humidity (55%) under a
regular 12-h day/night cycle (lights on at 8:00 a.m.; lights oﬀ at
8:00 p.m.). Standard laboratory rodent chow and water were
available ad libitum. Animals were habituated to testing
procedures for at least 3−4 days before experiments. For
intrathecal (i.th.) injections, rats were anesthetized using 2%
isoﬂurane with oxygen as the carrier gas (1 L/min). Rats were
placed in a stereotaxic frame and a small incision was made in the
atlanto-occipital membrane. A cannula was inserted into the
subarachnoid space, terminating in the L4−L5 region. Animals
received either 10 μL of clostridial chimera (100 ng) or vehicle
(saline). The cannula was then withdrawn and the wound closed
with suture clips. Local inﬂammation was induced by intraplantar
(i.pl.) injection of CFA (Sigma, Poole, UK; 50 μL) into the left
plantar surface of the hind paw, under isoﬂurane anesthesia as
above. During the injection the needle penetrated the skin just
distal to the targeted area and terminated at the center of the
plantar surface of the left hind paw. To assess mechanical
sensitivity following the development of inﬂammation, with-
drawal responses were measured with an automatic Von Frey
apparatus (Ugo-Basile, Italy). Animals were left to habituate to
the experimental room in their home cage for 20 min before the
beginning of each testing session. Each animal was tested 4 times
with a resting time of 5−10 min between each measurement. For
the automatic Von Frey, the ramp was set to reach the maximum
stimulus of 50 g in 20 s. Mechanical threshold at the central
plantar surface of the hind paw was assessed before the chimera
and CFA injections (as a basal pain threshold). The chimera was
ﬁrst injected intrathecally and the mechanical threshold was
assessed 3 days after the injection. Then, in the same group of rats
CFA was injected i.pl. and behavioral testing continued between
2 h and 11 days after CFA. During testing the observer was
blinded to the i.th. treatment. Data analysis and statistical
comparisons were performed using GraphPad Prism (GraphPad
Software, USA). Results are presented in the graphs as % of
control (basal pain threshold prior the i.th. injection) ± SEM.
Statistical analysis was performed by two-way analyses of
variance (ANOVA) with Bonferroni’s multiple comparison
posthoc tests, n = 6. A value of p < 0.05 was considered to be
statistically signiﬁcant.
Ethics Statement. Animal experiments were carried out
under license from the UK Home Oﬃce in accordance with the
Animals (Scientiﬁc Procedures) Act 1986 and in accordance with
the European Community Council Directive of November 24,
1986 (86/609/EEC).
■ RESULTS
To assess the ability of our fully synthetic tetanus toxin binding
domain (TBD) to bind central neurons, we prepared mCherry-
fused TBD as a single recombinant protein and incubated it with
cultured rat embryonic hippocampal neurons for 30 min. Figure
Figure 1.Assembly of the tetanus-botulinum chimera from two components. (A)mCherry-tagged tetanus binding domain (left) eﬃciently bindsmouse
hippocampal neurons in culture within 20 min (right). (B) Botulinum enzyme type A was stapled to the tetanus receptor binding domain using a
ﬂuorescently labeled stapling peptide (top schematic). Coomassie-stained SDS-PAGE gel (bottom) showing assembly of the clostridial chimera in the
presence of the stapling peptide in a 30-min reaction. The stapled product is resistant to SDS indicating an irreversible assembly.
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1A shows that mCherry-TBD bound to hippocampal neurons in
a robust way.
Next, we assembled the clostridial chimera from two separately
prepared parts: (i) botulinum type A protease/translocation unit
fused to a linker polypeptide, and (ii) TBD fused to a
complementary linker. The two linkers utilize SNARE-derived
peptides, which assemble spontaneously within minutes in the
presence of a stapling peptide.24,25 Figure 1B shows the typical
assembly reaction as visualized by SDS-PAGE. As expected from
the uniquely irreversible reaction, the chimera made of two
independent clostridial parts exhibited SDS-resistant properties.
Next we assessed the assembled clostridial chimera using
atomic force microscopy (AFM), which demonstrated uniform
dumbbell-shaped particles (Figure 2A). The topographic image
of individual particles and the proﬁle of the measured height
along their major axis presented two peaks, likely corresponding
to the two assembled clostridial chimera parts (Figure 2B).
Single-molecule analysis of a large number of individual particles
resulted in an average peak-to-peak distance of 14.6 nm (Figure
Figure 2.AFM imaging of the clostridial chimera. (A) AFM image showing a ﬁeld view of the stapled clostridial chimera (upper panel, scale bar 100 nm).
Four representative enlarged images of the clostridial chimera demonstrating the dumbbell-like shape of the molecule (lower panel, scale bar 20 nm).
The color-coded bar (right) indicates the height of the probed surface. (B) Single-molecule analysis of particles from selected topography images (upper
panel). The height proﬁle along the major axis (white line) was plotted and the peak-to-peak distance measured. (C) The distribution of a large number
of particles’ peak-to-peak distances (N = 108) has been plotted and ﬁtted to a Gaussian curve, which has a mean value of 14.6 nm. (D)Molecular model
of the clostridial chimera generated using the following structures available in the Protein Data Bank archive (http://www.rcsb.org): 3BTA (BoNT/A),
1N7S (SNARE complex), 1FV2 (TBD). The protein sequences have been truncated and/or joined according to the ‘Plasmids and sequences’ section in
the Experimental Procedures and then oriented and assembled using PyMol. The average peak-to-peak distance of 14.6 nm, obtained from the single-
molecule analysis, is visually compatible with the structure of the molecular model.
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2C). This value is consistent with the molecular model depicted
in Figure 2D. In this model the length of 14.6 nm equals the
distance between the approximate geometrical centers of the
botulinum protease/translocation unit and the TBD, assuming
they are kept apart and oriented by the assembled SNARE
complex. The molecular model, supported by the single-
molecule analysis, allowed us to estimate an apparent length of
the clostridial chimera of ∼23 nm.
To test the ability of the chimera to enter the nerve endings of
central neurons,26,27 we added it to cultured hippocampal
neurons and activated the neurons using 50 mM potassium
chloride for 10 min. The presynaptic uptake of the clostridial
chimera was assessed by colocalization with a synaptic vesicle
marker, synaptobrevin. Confocal microscopy of the neurons
revealed robust internalization of the chimera into the synaptic
endings of neurons (Figure 3A). Clostridial neurotoxins block
synaptic transmission by cleaving SNARE proteins at deﬁned
sites: the botulinum type A enzyme removes only 9 amino acids
from the C-terminus of the intraneuronal SNAP-25 protein, and
yet this is suﬃcient to block neurotransmitter release.10 The
ability of the clostridial chimera to translocate its botulinum
enzyme and cleave SNAP-25 was evaluated by immunoblotting.
Figure 3B shows that neuronal SNAP-25 was eﬃciently cleaved
by the chimera at concentrations in the low nanomolar range,
conﬁrming functionality of the assembled molecule.
To evaluate the biological activity of the chimera, we applied it
to mouse suprachiasmatic nucleus organotypic brain slices,
which exhibit circuit-driven circadian rhythms visualized using a
luciferase activity.17 Figure 4A shows that application of the
chimera at 5 nM led to a strong inhibition of circadian rhythms,
conﬁrming its ability to aﬀect native neuronal circuits. We
previously noted that structurally extended botulinum toxin type
A has a signiﬁcantly reduced paralytic ability, most likely because
Figure 3. The clostridial chimera penetrates synaptic endings and cleaves intraneuronal SNAP-25. (A) Confocal microscopy images (63×
magniﬁcation) showing colocalization of the ﬂuorescein-labeled chimera (green) with a synaptic vesicle marker, synaptobrevin (red), following KCl-
induced stimulation of cultured hippocampal neurons. Right panels show digitally zoomed details from the confocal images on the left. (B) Immunoblot
showing cleavage of SNAP-25 by the botulinum enzyme in hippocampal neurons following addition of the clostridial chimera at the indicated
concentrations (upper panel). Control reactions were carried out using the botulinum enzyme without tetanus binding domain. The graph (lower
panel) shows quantiﬁcation of the SNAP-25 cleavage measured by densitometry of the above immunoblot and indicates the EC50 for the chimera-
induced proteolysis being 2 nM.
Figure 4. Functional testing of the clostridial chimera in mouse tissues
ex vivo. (A) Circadian rhythms in ex vivo cultured mouse supra-
chiasmatic nucleus, visualized using a luciferase activity, are signiﬁcantly
damped following application of the clostridial chimera (5 nM). (B)
Comparison of the paralytic ability of the clostridial chimera and native
botulinum toxin type A (BoNT/A). Muscle twitch responses to nerve
stimulation were recorded for up to 4 h following application of BoNT/
A and the clostridial chimera at the indicated concentrations.
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of its inability to reach/penetrate neuromuscular junctions.13
Indeed while the LD50 of the native BoNT/A in mice is ∼5 pg,
peritoneal injections of ∼5 ng had no lethal eﬀect in mice.13
Further experiments, however, revealed that when injected in
mice in the range of 100−500 ng, the stapled botulinum toxin
leads to typical signs of botulism and death (data not shown).
We used isolated mouse hemidiaphragm muscles to assess the
paralysing ability of the new clostridial chimera. Figure 4B shows
that while picomolar amounts of native botulinum toxin readily
blocked muscle twitching, the clostridial chimera could only
achieve this eﬀect at nanomolar concentrations. We estimated
from the ﬁtted LD50 curve that the clostridial chimera is 11 000
times less eﬀective than the native toxin in causing neuro-
muscular paralysis. To conﬁrm the nonparalytic nature of the
chimera, we injected it either in a mouse thigh or intravenously at
500 ng, that is, 100 000-fold higher than the LD50 of native
botulinum toxin. All mice (n = 6) survived the injections and
none exhibited signs of paralysis.
Long-acting nonparalytic neuronal blocking agents could be
an excellent tool for silencing selected brain areas or spinal
regions both in research and in medicine, for example, for
treatment of drug-resistant epilepsy or chronic pain. For this
reason, we evaluated the ability of the chimera to inhibit cortical
activity in the rat visual cortex. The chimera (1 μL containing 7.5
ng) was pressure-injected in layer V of the visual cortex and
clostridial activity was ﬁrst assessed by tissue immunoblotting
and brain slice immunostaining, using an antibody that
recognizes only the cleaved SNAP-25 product.28 Figure 5A
shows that the cleaved SNAP-25 can only be detected in the
injection site, being restricted to a small area of the visual cortex
Figure 5. Clostridial chimera attenuates brain activity following localized injection into the rat visual cortex. (A) Schematic diagram showing the
injection site of the chimera (left). The brain areas tested were subjected to immunoblot analysis revealing the cleaved SNAP-25 product only in the
chimera-injected, but not in vehicle-treated cortex (control). Staining with the anti-α-tubulin antibody indicates equal loading of brain-derived material.
(B) Confocal microscopy images of immunostained brain slices showing localized cleavage of SNAP-25 (in red) 4 days following the injection. The
yellow contour delineates an intense immunoﬂuorescence observed for the cleaved SNAP-25 product (left panel). YoYo-1 nuclear staining (green) was
used to highlight the brain structure (middle panel); the yellow line in the right panel indicates the pipet track. Scale bar = 120 μm. (C) The amplitude of
visual evoked potentials (VEPs) as a function of variable contrast (K20−K90) is strongly reduced following the injection of the chimera (left, n = 5) but
not the vehicle (right, n = 4) in the visual cortex. The internal standard in each experiment consisted of VEPs measured far (>500 um) from the injection
site (blue). In vehicle-injected rats there is no diﬀerence between contrast curves measured either close to (red) or far from (blue) the injection site (two-
way ANOVA, p = 0.41). On the contrary, in the chimera-injected rats, the contrast curve recorded at the injection site displays signiﬁcantly lower VEP
values (two-way ANOVA, p = 0.006 followed by Holm-Sidak test, p < 0.05). Data are expressed as mean ± SEM.
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extending from layer V up to the pipet penetration point. Lateral
spread of toxin (delineated in yellow in Figure 5B) was
consistently less than 1 mm in coronal sections of the infused
hemisphere. Next, visually evoked potentials (VEPs) were
recorded either around the toxin delivery site or at a distance
>500 μm from the injection, 4−8 days after toxin delivery. We
found that visual responsiveness (i.e., the VEP signal-to-noise
ratio21,29) was substantially dampened within the aﬀected cortex
as compared to distant regions (Figure 5C, left). VEPs were
signiﬁcantly reduced across a range of stimulus contrasts (two-
way ANOVA, p = 0.006, followed by Holm Sidak test, p < 0.05;
Figure 5C, left). No alterations in visual responsiveness in the
treated area were found in animals injected with vehicle solution
(two-way ANOVA, p = 0.41; Figure 5C, right), conﬁrming that
the new clostridial chimera can attenuate neuronal activity in a
small, selected area of the brain.
The most promising use of long-acting nonparalytic neuronal
blocking agents would be in the treatment of prolonged pain.30
We evaluated the ability of the clostridial chimera to reduce
mechanical hypersensitivity triggered by injection of an
inﬂammatory substance into the hind paw of rats. The clostridial
chimera (100 ng) was delivered at the L4-L5 level of the rat spinal
cord intrathecally in a volume of 10 μL. Following the injections,
rats exhibited neither spastic nor ﬂaccid paralysis, indicating that
tetanic muscle spasms are a speciﬁc feature of the motor neuron
route that tetanus toxin normally exploits to reach the ventral
horn of the spinal cord.10 Three days after the clostridial chimera
injections, basal mechanical sensitivity thresholds were evaluated
using an automatic von Frey apparatus. This revealed no change
in acute mechanical nociception (Figure 6A).
Next, these rats were injected with Complete Freund’s
Adjuvant (CFA) into the hind paw and inﬂammation-induced
mechanical hypersensitivity was assessed for up to 11 days
(Figure 6A). Compared to the control group injected with saline,
rats that had received intrathecal injection of the chimera
exhibited signiﬁcant reduction of mechanical hypersensitivity.
This eﬀect was observed from 24 h after CFA injection and lasted
for as long as 11 days after CFA injection, which can be explained
by the long-lasting botulinum proteolytic eﬀects.2,10 To
determine the proportion of sensory neurons aﬀected, we
exposed cultured rat dorsal root ganglion neurons to the chimera
and assessed cleavage of SNAP-25 using an antibody against the
intact N-terminus of SNAP-25.31 Figure 6B shows that even at
high concentrations approximately half of the SNAP-25
remained intact, suggesting that a population of sensory neurons
is resistant to the chimera. It has been reported that mechanical
sensitivity is transduced by the IB4-lectin-binding neurons.32 We
evaluated whether the IB4 lectin and the TBD bind the same
population of dorsal root ganglion neurons. Remarkably, the
TBD and IB4 bound to two populations of sensory neurons in a
mutually exclusively manner (Figure 6C). This result indicates
that pain-conducting mechanoreceptors in the rat belong to
tetanus- rather than IB4-binding neurons.
■ DISCUSSION
Silencing selected neuronal populations in deﬁned areas of the
CNS is important for both research and medicine. Clostridial
molecules which inactivate the synaptic release machinery oﬀer
an opportunity to design long-acting neuronal blocking agents.
The ﬁrst step toward utilization of clostridial molecules for
selective neuronal blockade is to remove their highly potent
neuromuscular paralytic activity. Here we present the ﬁrst
clostridial chimera which does not cause muscle paralysis in
mammals and yet eﬃciently blocks CNS functions. The rational
design of the chimera depended on three basic pieces of
knowledge. First, the botulinum enzyme together with its
translocation domain is highly eﬀective in causing long-lasting
blockade of neurotransmitter release.1 Second, introduction of
the linking system within the redesigned botulinum molecule
signiﬁcantly diminishes its paralytic activity.13 Third, the tetanus
binding domain targets central neurons without aﬀecting the
neurotransmitter release machinery at neuromuscular junc-
tions.10 Combination of these three properties allowed us to
achieve a nonparalytic neuronal blocking agent.
The potential uses of the new clostridial chimera for
neurobiology and medicine are likely to be diverse: here we
would like to highlight several potential applications. First, native
botulinum toxin type A (e.g., BOTOX, Allergan) is now used for
the treatment of chronic migraine. Although BOTOX eﬃciently
induces neuromuscular paralysis in all patients injected, only half
report adequate relief from migraine symptoms.33,34 This result
suggests that the medicinal properties of botulinum molecules
Figure 6. Intrathecally delivered clostridial chimera reduces mechanical
hypersensitivity in a rat model of inﬂammatory pain. (A) Graph showing
relative rat paw mechanical sensitivity measured using an automatic von
Frey apparatus. The clostridial chimera (100 ng) was injected
intrathecally (i.th.) at the L4-L5 level of spinal cord (red diamonds, n
= 6). Control rats (blue squares) received i.th. injection of vehicle
(saline). CFA was injected into left hind paw (intraplantar, i.pl.) and
mechanical hypersensitivity was assessed between 2 h and 11 days after
CFA. BS1 − basal pain threshold prior to i.th. injections; BS2 − basal
pain threshold three days after i.th. injections. Data are expressed as % of
control (basal pain threshold prior to the i.th. injection) ± SEM. (B)
Immunoblot showing that the clostridial chimera even at high
concentrations cleaves only 50% of neuronal SNAP-25, suggesting a
degree of speciﬁcity in neuronal targeting by the chimera. (C) Confocal
microscopy images of cultured dorsal root ganglion neurons, exposed to
both the clostridial chimera and IB4 lectin, demonstrate that the
clostridial chimera targets an IB4-lectin negative subpopulation of the
sensory cells.
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are not always based on their paralytic action at neuromuscular
junctions. Indeed, we and others have reported that peripheral
injections of clostridial molecules can aﬀect a diverse set of
neurons, ranging from sensory primary aﬀerents to central
neurons.3,35,36 Clearly, a nonparalytic molecule which targets
speciﬁc neurons will be invaluable in delineating the neuronal
circuits that are important in chronic pain conditions. Further
work on a wide variety of pain conditions (neuropathic,
inﬂammatory, postoperative symptoms, etc.) will be necessary
to provide new insights into the mechanisms of pain generation,
its longevity, and potential treatment. Second, a sizable
proportion of people with epilepsy suﬀer from drug-resistant
focally generated seizures, with surgical removal of the aﬀected
brain areas being the only option to treat some of these
patients.37,38 It can be envisioned that safe delivery of a
nonparalytic clostridial chimera into spatially deﬁned regions
measuring as little as one cubic millimeter might be eﬀective in
blocking seizure-generating areas for several months. Such a
silencing eﬀect could be a relatively noninvasive means of
predicting the likelihood that surgery would be successful, and
might even be suﬃciently eﬀective to rewire and permanently
disable seizure-generating circuits, thereby avoiding the need for
surgery.
Here, we have demonstrated for the ﬁrst time that the newly
introduced ‘protein stapling’ technique allows creation of a safe
neuronal blocking agent. Development of new synthetic
neuronal blocking agents with enhanced functions which can
be injected into desired areas opens new avenues for probing
nerve functions not only in rodents, but also in higher
organismsa requirement in our quest to understand the
human brain.39,40
■ AUTHOR INFORMATION
Corresponding Author
*E-Mail: b.davletov@sheﬃeld.ac.uk; Tel.: +44-114-2225111.
Author Contributions
Enrico Ferrari, Chunjing Gu, Dhevahi Niranjan contributed
equally to the study.
Notes
The authors declare no competing ﬁnancial interest.
■ ACKNOWLEDGMENTS
This study was supported by the MRC grant U10578791 and
Wellcome Trust Grant No. 089125/Z/09/Z. We thank David
Menon and PeterMcNaughton for helpful discussions. We thank
Richard Berks, Claire Knox, and Angela Middleton for their help
with the biological tests.
■ ABBREVIATIONS
AFM, Atomic Force Microscopy; ANOVA, Analysis of Variance;
BoNT/A, Botulinum Neurotoxin type A; CFA, Complete
Freund’s Adjuvant; CNS, Central Nervous System; DRG, Dorsal
Root Ganglia; HBSS, Hanks’s Balanced Salt Solution; HRP,
Horseradish Peroxidase; MEM, Minimum Essential Medium;
NGF, Nerve growth factor; PBS, Phosphate Buﬀered Saline;
SDS, Sodium Dodecyl Sulfate; SDS-PAGE, Sodium Dodecyl
Sulfate; PAGE, Polyacrylamide Gel Electrophoresis; SEM,
Standard Error of the Mean; SNAP-25, Synaptosomal-associated
protein of 25 kDa; SNARE, SNAP Soluble NSF Attachment
Protein Receptor; TAMRA, Carboxytetramethylrhodamine;
TBD, Tetanus Binding Domain; VEP, Visual Evoked Potential
■ REFERENCES
(1) Foster, K. A. (2009) Engineered Toxins: New Therapeutics.
Toxicon 54, 587−592.
(2) Dolly, J. O., Lawrence, G. W., Meng, J., Wang, J., and Ovsepian, S.
V. (2009) Neuro-Exocytosis: Botulinum Toxins as Inhibitory Probes
and Versatile Therapeutics. Curr. Opin. Pharmacol. 9, 326−335.
(3) Stockel, K., Schwab, M., and Thoenen, H. (1975) Comparison
Between the Retrograde Axonal Transport of Nerve Growth Factor and
Tetanus Toxin in Motor, Sensory and Adrenergic Neurons. Brain. Res
99, 1−16.
(4) Davletov, B., Bajohrs, M., and Binz, T. (2005) Beyond BOTOX:
Advantages and Limitations of Individual Botulinum Neurotoxins.
Trends Neurosci. 28, 446−452.
(5) Binz, T., and Rummel, A. (2009) Cell Entry Strategy of Clostridial
Neurotoxins. J. Neurochem. 109, 1584−1595.
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